Allena Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
-- Successfully Completed Initial Public Offering, Raising $74.9 Million in Gross Proceeds -- Presented Final Results from Phase 2 Trials of ALLN-177 in Secondary Hyperoxaluria at ASN Kidney Week 2017 -- Received Orphan Drug Designation from the U.S. …